Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;20(3):285–290. doi: 10.1002/clc.4960200318

A practical approach to torsade de pointes

Dan M Roden 1,✉
PMCID: PMC6656095  PMID: 9068917

Abstract

The term torsade de pointes refers to polymorphic ventricular tachycardia that occurs in the setting of an abnormally long QT interval. While the most common cause is treatment with QT prolonging drugs, torsade de pointes also occurs in the congenital long QT syndromes and in the setting of acquired heart block or severe electrolyte disturbance, notably hypokalemia. Among QT prolonging drugs that cause torsade de pointes, both antiarrhythmics and “noncardioactive” drugs have been recognized. The electrocardiographic features of torsade de pointes include labile QT intervals, prominent U waves, and a “pause‐dependent” onset of the arrhythmia. Treatment consists of recognition of the syndrome, correction of underlying electrolyte abnormalities, and withdrawal of any offending drugs. Magnesium, isoproterenol, or cardiac pacing provides specific antiarrhythmic therapy in torsade de pointes.

Keywords: long QT syndrome, torsade de pointes, proarrhythmia

Full Text

The Full Text of this article is available as a PDF (796.7 KB).

References

  • 1. Lewis T, Drury AN, Wedd AM, Iliescu CC: Observations upon the action of certain drugs upon fibrillation of the auricles. Heart 1922; 9: 207–267. [Google Scholar]
  • 2. Jervell A, Lange‐Nielsen F: Congenital deaf‐mutism, functional heart disease with prolongation of the Q‐T interval and sudden death. Am Heart J 1957; 54: 59–68. [DOI] [PubMed] [Google Scholar]
  • 3. Romano C, Gemme G, Pongiglione R: Aritmie cardiache rare in eta' pediatrica. Clin Pediatr 1963; 45: 656–683. [PubMed] [Google Scholar]
  • 4. Ward OC: A new familial cardiac syndrome in children. J Irish Med Assoc 1964; 54: 103–106. [PubMed] [Google Scholar]
  • 5. Selzer A, Wray HW: Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17–30. [DOI] [PubMed] [Google Scholar]
  • 6. Dessertenne F: La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966; 59: 263–272. [PubMed] [Google Scholar]
  • 7. Zwillinger L: Über die Magnesiumwirkung auf das Herz. Klin Wochenschr 1935; 40: 1429–1433. [Google Scholar]
  • 8. Horowitz LN, Greenspan AM, Spielman SR, Josephson ME: Torsade de pointes: Electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities. Circulation 1981; 63: 1120–1128. [DOI] [PubMed] [Google Scholar]
  • 9. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M: Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543–1551. [DOI] [PubMed] [Google Scholar]
  • 10. Koster RW, Wellens HJJ: Quinidine‐induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 1976; 38: 519–523. [DOI] [PubMed] [Google Scholar]
  • 11. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM: Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984; 107: 425–430. [DOI] [PubMed] [Google Scholar]
  • 12. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine‐associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111: 1088–1093. [DOI] [PubMed] [Google Scholar]
  • 13. Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Vincent GM, For the SADS Foundation Task Force on LQTS : Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996–2012. [DOI] [PubMed] [Google Scholar]
  • 14. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT: Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Molec Gen 1995; 4: 1603–1607. [DOI] [PubMed] [Google Scholar]
  • 15. Bennett PB, Yazawa K, Makita N, George AL Jr: Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376: 683–685. [DOI] [PubMed] [Google Scholar]
  • 16. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795–803. [DOI] [PubMed] [Google Scholar]
  • 17. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996; 12: 17–23. [DOI] [PubMed] [Google Scholar]
  • 18. Roden DM: Current status of class III antiarrhythmic therapy. Am J Cardiol 1993; 72: 44B–49B. [DOI] [PubMed] [Google Scholar]
  • 19. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr: Implications for torsade de pointes and reverse use‐dependence. Circulation 1996; 93: 407–411. [DOI] [PubMed] [Google Scholar]
  • 20. Sanguinetti MC, Jurkiewicz NK: Role of external Ca2+ and K+ in gating of cardiac delayed rectifier K+ currents. Pflügers Arch 1992; 420: 180–186. [DOI] [PubMed] [Google Scholar]
  • 21. Campbell RW, Furniss SS: Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Am J Cardiol 1993; 72: 80A–85A. [DOI] [PubMed] [Google Scholar]
  • 22. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB: Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86: 1376–1382. [DOI] [PubMed] [Google Scholar]
  • 23. Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: The role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23: 259–277. [DOI] [PubMed] [Google Scholar]
  • 24. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL: Torsade de pointes: The long‐short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983; 2: 806–817. [DOI] [PubMed] [Google Scholar]
  • 25. Locati EH, Maison‐Blanche P, Dejode P, Cauchemez B, Coumel P: Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: Quantitative analysis of Hotter recordings. J Am Coll Cardiol 1995; 25: 1564–1575. [DOI] [PubMed] [Google Scholar]
  • 26. Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI: Torsade de pointes with Almokalant, a new class III antiarrhythmic drug. Am Heart J 1993; 126: 1008–1011. [DOI] [PubMed] [Google Scholar]
  • 27. Bazett HC: An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353–370. [Google Scholar]
  • 28. Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF: Amiodarone in patients with previous drug‐mediated torsade de pointes. Ann Intern Med 1989; 111: 574–580. [DOI] [PubMed] [Google Scholar]
  • 29. Lazzara R: Amiodarone and torsade de pointes. Ann Intern Med 1989; 111: 549–551. [DOI] [PubMed] [Google Scholar]
  • 30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J Am Med Assoc 1993; 270: 2590–2597. [DOI] [PubMed] [Google Scholar]
  • 31. Vincent GM, Timothy KW, Leppert M, Keating M: The spectrum of symptoms and QT intervals in carriers of the gene for the long‐QT syndrome. N Engl J Med 1992; 327: 846–852. [DOI] [PubMed] [Google Scholar]
  • 32. Choy AMJ, Darbar D, Dell'Orto S, Roden DM: Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. Circulation 1996; 94: I202. [Google Scholar]
  • 33. Hohnloser SH, Arendts W, Quart B, Bristol Myers Squibb Research Institute : Incidence, type, and dose‐dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF(abstr). PACE 1992; 15: 551. [Google Scholar]
  • 34. Hohnloser SH, Woosley RL: Sotalol. N Engl J Med 1994; 331: 31–38. [DOI] [PubMed] [Google Scholar]
  • 35. Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, Ruo TI, Asada A, Talano JV, Atkinson AJ: Torsade de pointes induced by N‐acetylprocainamide. J Am Coll Cardiol 1984; 4: 621–624. [DOI] [PubMed] [Google Scholar]
  • 36. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, The Ibutilide Repeat Dose Study Investigators : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–1621. [DOI] [PubMed] [Google Scholar]
  • 37. Roden DM: Ibutilide and the treatment of atrial arrhythmias: A new drug—almost unheralded—is now available to US physicians. Circulation 1996; 94: 1499–1502. [DOI] [PubMed] [Google Scholar]
  • 38. Woosley RL, Chen Y, Freiman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc 1993; 269: 1532–1536. [PubMed] [Google Scholar]
  • 39. Roy ML, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94: 817–823. [DOI] [PubMed] [Google Scholar]
  • 40. Roden DM, George AL Jr, Bennett PB: Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol 1995; 6: 1023–1031. [DOI] [PubMed] [Google Scholar]
  • 41. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller‐Linhardt G: Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993; 27: 2186–2193. [DOI] [PubMed] [Google Scholar]
  • 42. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R: Bradycardia‐dependent triggered activity: Relevance to drug‐induced multiform ventricular tachycardia Circulation 1983; 68: 846–856. [DOI] [PubMed] [Google Scholar]
  • 43. Roden DM, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985; 56: 857–867. [DOI] [PubMed] [Google Scholar]
  • 44. Tzivoni D, Banai S, Schugar C, Benhorin J, Keren A, Gottlieb S, Stern S: Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392–397. [DOI] [PubMed] [Google Scholar]
  • 45. Schwartz PJ, Zaza A, Locati E, Moss AJ: Stress and sudden death. The case of the long QT syndrome. Circulation 1991; 83: II71–II80. [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES